Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. Based in New York.
Oramed Pharmaceuticals: sales sharply down (−100.0%), net income sharply up (+1,962.8%), cash flow sharply up (+55.8%).
- Sales sharply downH1 2026
Revenue: $0M, vs. $2M a year earlier, i.e. −100.0%.
- Net income sharply upH1 2026
Net income: $116M, vs. $6M a year earlier, i.e. +1,962.8%.
- Cash flow sharply upH1 2026
Operating cash flow: $−3M, vs. $−7M a year earlier, i.e. +55.8%.
- Operating income upH1 2026
Operating income: $−6M, vs. $−7M a year earlier, i.e. +8.1%.
What the market pays, vs. the sector
This company's valuation multiples history is being built day by day from now on.
P/E calculated on net income (trailing 12 months: last fiscal year + H1 2026 − same period a year earlier). Sector median: companies in the group tracked here. Prices: Yahoo Finance; market cap cross-checked with the Tel Aviv Stock Exchange for Israeli stocks. These ratios describe a price, not a value: none of them says whether the share is expensive or cheap.
Dividend per share, over 5 years
Total dividends per share paid each calendar year (0 year(s) out of 5 with a payment). Source: Yahoo Finance. The current year is not complete.
Follow earnings · WhatsApp group TA-125Details ▾
Every report from a TA-125 company, analyzed the same day: key figures and year-on-year change, analysis in brief, share price reaction. One daily summary during earnings season.
Join the TA-125 groupDetailed figures and history
Financial summary
| S1 2026 | S1 2025 | FY 2025 | |
|---|---|---|---|
| Total assets | 370 | 162 | 231 |
| Current assets | 53 | 99 | 133 |
| Non-current assets | 316 | 63 | 98 |
| Equity | 317 | 154 | 200 |
| of which minority interests | 0 | −1 | 0 |
| Current liabilities | 11 | 4 | 19 |
| Non-current liabilities | 41 | 4 | 12 |
| Revenue | 0 | 2 | 2 |
| Gross profit | 0 | 0 | 0 |
| Operating income | −6 | −7 | −15 |
| Pre-tax income | 151 | 6 | 75 |
| Net income | 116 | 6 | 64 |
| Net income (attributable to shareholders) | 116 | 6 | 64 |
| Dividends paid | 0 | 0 | −11 |
| Operating cash flow | −3 | −7 | −9 |
In millions of dollars. The "H1" columns cover the first six months of the year.
Calculated from these figures
| S1 2026 | S1 2025 | FY 2025 | |
|---|---|---|---|
| Gross margin | — | 0.7% | 0.7% |
| Operating margin | — | −349.4% | −754.4% |
| Net margin | — | 282.3% | 3,202.5% |
| Current ratio (current assets / current liabilities) | 5,0 x | 26,8 x | 7,0 x |
| Equity / total assets | 85.9% | 95.0% | 86.5% |
The 5-year history, charts and cross-check models are coming for companies listed only in Tel Aviv: each new filing on Maya is kept and enriches the page.
Company overview
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Source: official company profile (Yahoo Finance), summary. Website: oramed.com
- Maya, Tel Aviv Stock Exchange: company page and reports